CF3CN

Unknown Manufacturer

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA
EP 4665335 A1Applicant: ONTRACK THERAPEUTICS LTDPriority: 2023
CN
EP
US
WO
4 publications
DRUG FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE
- EP 4772512 A1
  Applicant: SHENZHEN UNIV OF ADVANCED TECHNOLOGYPriority: 2023
  EP
  US
  WO
  3 publications
- CN 117343071 A
  Applicant: SHENZHEN UNIV OF TECHNOLOGYPriority: 2023
  CN
4-(6-OXO-2-(TRIFLUOROMETHYL)-3,6-DIHYDROCHROMENO[7,8-D]IMIDAZOL-8-YL)BENZONITRILE FOR USE IN THE TREATMENT OF POSITIVE SYMPTOMS IN SCHIZOPHRENIA
WO 2025109339 A1Applicant: ONTRACK THERAPEUTICS LTDPriority: 2023
CN
WO
2 publications
4-(6-OXO-2-(TRIFLUOROMETHYL)-3,6-DIHYDROCHROMENO[7,8-D]IMIDAZOL-8-YL)BENZONITRILE FOR USE IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH MOVEMENT DISORDERS
US 20250170103 A1Applicant: ONTRACK THERAPEUTICS LTDPriority: 2022
US
SALT FORMS OF A CHROMENE COMPOUND
WO 2025109338 A1Applicant: ONTRACK THERAPEUTICS LTDPriority: 2023
WO
USE OF INHIBITOR OF TRANSCRIPTION FACTOR C/EBPβ IN PREPARING MEDICAMENT FOR TREATING POSTMENOPAUSAL OSTEOPOROSIS
WO 2026137413 A1Applicant: SHENZHEN UNIV OF ADVANCED TECHNOLOGYPriority: 2024
WO
Application of transcription factor C/EBP beta inhibitor in preparation of medicine for treating postmenopausal osteoporosis
CN 122307108 AApplicant: SHENZHEN UNIV OF TECHNOLOGYPriority: 2024
CN